Ecromeximab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | GD3 ganglioside |
| Identifiers | |
| CAS Number | 292819-64-8  |
| ATC code | none |
| UNII | M76FX2JZRM  |
| Chemical data | |
| Molecular mass | 145,255 Daltons |
| (what is this?) (verify) |
|
Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]
This drug was developed by Kyowa Hakko Kogyo Co., Ltd.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
- ↑ Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
